LINC00973/DTX3L Axis Promotes Non-Small Cell Lung Cancer Progression and Serves as a Therapeutic Target

Abstract

Long non-coding RNAs (lncRNAs) constitute a critical class of regulatory molecules involved in cancer biology and play pivotal roles in tumor initiation and progression. Nevertheless, the biological functions of many newly identified lncRNAs in non-small cell lung cancer (NSCLC), as well as their potential therapeutic relevance, remain insufficiently characterized. In this study, high-throughput sequencing analysis of paired NSCLC tumor tissues and adjacent non-tumorous samples revealed that LINC00973 is significantly upregulated in tumor specimens. Moreover, elevated LINC00973 expression was found to be closely associated with poor clinical outcomes in patients with NSCLC. Functional assays showed that LINC00973 knockdown inhibits NSCLC cell proliferation, migration, and invasion while inducing apoptosis, whereas overexpression produces opposite effects. These observations were confirmed in vivo, where LINC00973 depletion markedly suppressed tumor growth and metastasis. Mechanistically, LINC00973 interacts with and stabilizes deltex E3 ubiquitin ligase 3L (DTX3L), preventing its ubiquitination-mediated degradation and activating the AKT signaling pathway. Therapeutically, RGD-modified exosome-mediated delivery of LINC00973 siRNA significantly inhibited NSCLC progression in mouse models. Moreover, a synthetic biology-based strategy enabling hepatic production of exosomes carrying LINC00973-targeting siRNA achieved robust anti-tumor effects. Together, these findings establish LINC00973 as an oncogenic lncRNA that promotes NSCLC progression via DTX3L stabilization and highlight LINC00973 as a promising therapeutic target.

Keywords

DTX3L / LINC00973 / non-small cell lung cancer / targeted therapy

References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72 (2022): 7–33.

[2] Z. Xi, H. Huang, J. Hu, et al., “LINC00571 Drives Tricarboxylic Acid Cycle Metabolism in Triple-Negative Breast Cancer Through HNRNPK/ILF2/IDH2 Axis,” Journal of Experimental & Clinical Cancer Research 43 (2024): 22.

[3] G. Wu, J. Su, L. Zeng, et al., “LncRNA BCAN-AS1 Stabilizes c-Myc via N⁶-Methyladenosine-Mediated Binding With SNIP1 to Promote Pancreatic Cancer,” Cell Death & Differentiation 30 (2023): 2213–2230.

[4] X. X. Cai, G. M. Chen, Z. Q. Zheng, et al., “Transcriptional Landscape and Predictive Potential of Long Noncoding RNAs in Peritoneal Recurrence of Gastric Cancer,” Molecular Cancer 23 (2024): 284.

[5] L. L. Chen and V. N. Kim, “Small and Long Non-Coding RNAs: Past, Present, and Future,” Cell 187 (2024): 6451–6485.

[6] J. Beermann, M. T. Piccoli, J. Viereck, and T. Thum, “Non-Coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches,” Physiological Reviews 96 (2016): 1297–1325.

[7] X. Huang, W. Wu, D. Jing, et al., “Engineered Exosome as Targeted lncRNA MEG3 Delivery Vehicles for Osteosarcoma Therapy,” Journal of Controlled Release 343 (2022): 107–117.

[8] Y. Wang, J. Zhang, H. Shi, et al., “M2 Tumor-Associated Macrophages-Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression,” Advanced Science 11 (2024): 2309298.

[9] Q. Zhu, C. Zhang, T. Qu, et al., “MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer,” Cancer Research 82 (2022): 4340–4358.

[10] Y. Li, Y. Shen, M. Xie, et al., “LncRNAs LCETRL3 and LCETRL4 at Chromosome 4q12 Diminish EGFR-TKIs Efficiency in NSCLC Through Stabilizing TDP43 and EIF2S1,” Signal Transduction and Targeted Therapy 7 (2022): 30.

[11] Q. Yang, M. Wang, J. Xu, et al., “LINC02159 Promotes Non-Small Cell Lung Cancer Progression via ALYREF/YAP1 Signaling,” Molecular Cancer 22 (2023): 122.

[12] Y. Q. Ao, J. Gao, J. H. Jiang, H. K. Wang, S. Wang, and J. Y. Ding, “Comprehensive Landscape and Future Perspective of Long Noncoding RNAs in Non-Small Cell Lung Cancer: It Takes a Village,” Molecular Therapy 31 (2023): 3389–3413.

[13] K. Yang, W. Zhang, L. Zhong, et al., “Long Non-Coding RNA HIF1A-As2 and MYC Form a Double-Positive Feedback Loop to Promote Cell Proliferation and Metastasis in KRAS-Driven Non-Small Cell Lung Cancer,” Cell Death & Differentiation 30 (2023): 1533–1549.

[14] Y. Liang, L. Duan, J. Lu, and J. Xia, “Engineering Exosomes for Targeted Drug Delivery,” Theranostics 11 (2021): 3183–3195.

[15] M. Zhang, S. Hu, L. Liu, et al., “Engineered Exosomes From Different Sources for Cancer-Targeted Therapy,” Signal Transduction and Targeted Therapy 8 (2023): 124.

[16] J. Zhang, C. Ji, H. Zhang, et al., “Engineered Neutrophil-Derived Exosome-Like Vesicles for Targeted Cancer Therapy,” Science Advances 8 (2022): eabj8207.

[17] Y. Chen, L. Gong, Y. Cao, et al., “Reprogramming Tumor-Associated Macrophages by a Dually Targeted Milk Exosome System as a Potent Monotherapy for Cancer,” Journal of Controlled Release 366 (2024): 395–409.

[18] S. Qin, Y. Liu, G. He, et al., “Spatiotemporal Delivery of Dual Nanobodies by Engineered Probiotics to Reverse Tumor Immunosuppression via Targeting Tumor-Derived Exosomes,” ACS Nano 18 (2024): 26858–26871.

[19] J. F. Creeden, J. Sevier, J. T. Zhang, et al., “Smart Exosomes Enhance PDAC Targeted Therapy,” Journal of Controlled Release 368 (2024): 413–429.

[20] X. Fu, Y. Shi, H. Wu, et al., “Inhalable Liposomal Delivery of Osimertinib and DNA for Treating Primary and Metastasis Lung Cancer,” Nature Communications 16 (2025): 3336.

[21] N. L. Syn, L. Wang, E. K. Chow, C. T. Lim, and B. C. Goh, “Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges,” Trends in Biotechnology 35 (2017): 665–676.

[22] D. Yang, W. Zhang, H. Zhang, et al., “Progress, Opportunity, and Perspective on Exosome Isolation—Efforts for Efficient Exosome-Based Theranostics,” Theranostics 10 (2020): 3684–3707.

[23] Y. Sun, Y. Zhao, X. Ni, et al., “In Vivo Self-Assembled Small RNA Targets H19 lncRNA for the Treatment of Colorectal Cancer,” Journal of Controlled Release 358 (2023): 142–160.

[24] W. X. Peng, P. Koirala, and Y. Y. Mo, “LncRNA-Mediated Regulation of Cell Signaling in Cancer,” Oncogene 36 (2017): 5661–5667.

[25] W. Hu, Y. Hu, Y. Pei, et al., “Silencing DTX3L Inhibits the Progression of Cervical Carcinoma by Regulating PI3K/AKT/mTOR Signaling Pathway,” International Journal of Molecular Sciences 24 (2023): 861.

[26] Z. Fu, X. Zhang, X. Zhou, et al., “In Vivo Self-Assembled Small RNAs as a New Generation of RNAi Therapeutics,” Cell Research 31 (2021): 631–648.

[27] H. Pei, Y. Dai, Y. Yu, et al., “The Tumorigenic Effect of lncRNA AFAP1-AS1 Is Mediated by Translated Peptide ATMLP Under the Control of m⁶A Methylation,” Advanced Science 10 (2023): 2300314.

[28] R. Cheng, F. Li, M. Zhang, et al., “A Novel Protein RASON Encoded by a lncRNA Controls Oncogenic RAS Signaling in KRAS Mutant Cancers,” Cell Research 33 (2023): 30–45.

[29] Q. Wang, C. Chen, X. Xu, et al., “APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly,” Advanced Science 9 (2022): 2201889.

[30] Q. Guo, D. Li, X. Luo, et al., “The Regulatory Network and Potential Role of LINC00973-miRNA-mRNA ceRNA in the Progression of Non-Small-Cell Lung Cancer,” Frontiers in Immunology 12 (2021): 684807.

[31] H. Wang, K. Lin, L. Zhu, et al., “Oncogenic lncRNA LINC00973 Promotes Warburg Effect by Enhancing LDHA Enzyme Activity,” Science Bulletin 66 (2021): 1330–1341.

[32] F. Shao, Y. Gao, W. Wang, et al., “Silencing EGFR-Upregulated Expression of CD55 and CD59 Activates the Complement System and Sensitizes Lung Cancer to Checkpoint Blockade,” Nature Cancer 3 (2022): 1192–1210.

[33] J. S. Mattick, P. P. Amaral, P. Carninci, et al., “Long Non-Coding RNAs: Definitions, Functions, Challenges and Recommendations,” Nature Reviews Molecular Cell Biology 24 (2023): 430–447.

[34] Q. Ye, J. Ma, Z. Wang, et al., “DTX3L-Mediated TIRR Nuclear Export and Degradation Regulates DNA Repair Pathway Choice and PARP Inhibitor Sensitivity,” Nature Communications 15 (2024): 10596.

[35] K. Zhu, M. J. Suskiewicz, A. Hloušek-Kasun, et al., “DELTEX E3 Ligases Ubiquitylate ADP-Ribosyl Modification on Protein Substrates,” Science Advances 8 (2022): eadd4253.

[36] R. Li, N. Li, Q. Yang, et al., “Spatial Transcriptome Profiling Identifies DTX3L and BST2 as Key Biomarkers in Esophageal Squamous Cell Carcinoma Tumorigenesis,” Genome Medicine 16 (2024): 148.

[37] S. B. Bachmann, S. C. Frommel, R. Camicia, H. C. Winkler, R. Santoro, and P. O. Hassa, “DTX3L and ARTD9 Inhibit IRF1 Expression and Mediate in Cooperation With ARTD8 Survival and Proliferation of Metastatic Prostate Cancer Cells,” Molecular Cancer 13 (2014): 125.

[38] P. Hu, L. Lin, T. Huang, et al., “Circular RNA circEYA3 Promotes the Radiation Resistance of Hepatocellular Carcinoma via the IGF2BP2/DTX3L Axis,” Cancer Cell International 23 (2023): 308.

[39] Y. Xie, Y. Sun, Y. Liu, et al., “Targeted Delivery of RGD-CD146⁺ CD271⁺ Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Promotes Blood-Spinal Cord Barrier Repair After Spinal Cord Injury,” ACS Nano 17 (2023): 18008–18024.

[40] F. J. Slack and A. M. Chinnaiyan, “The Role of Non-Coding RNAs in Oncology,” Cell 179 (2019): 1033–1055.

[41] X. Zhou, M. Yu, L. Ma, et al., “In Vivo Self-Assembled siRNA as a Modality for Combination Therapy of Ulcerative Colitis,” Nature Communications 13 (2022): 5700.

RIGHTS & PERMISSIONS

2026 The Author(s). Smart Medicine published by Wiley-VCH GmbH on behalf of Wenzhou Institute, University of Chinese Academy of Sciences.